This is because it offers a lot of medical competence, sophisticated facilities, and low costs. Patients from all around the world are selecting India more and more, not only because it has advanced therapies, but also because it is cheaper.
Not many institutions offer stem cell therapy for kidney cancer as a standard treatment, but many are doing clinical studies or making individualized treatment programs for patients who qualify.
The Journey Of A Patient And The Treatment Process In India
The Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT) set rules for how stem cells can be used for medical reasons in India. These rules make ensuring that therapies are done in a way that is fair and that puts the safety of the patient first. Only clinical trials that have been filed and approved are allowed to give stem cell therapy for cancer. Patients should also check the qualifications of any hospital or clinic before getting treatment. Ethical issues also include where stem cells come from. For most treatments, adult stem cells are preferable to avoid ethical issues with embryonic stem cells.
The Future of Stem Cell Therapy for Kidney Cancer in India
Combining kidney cancer stem cell treatment in India with artificial intelligence, genetic engineering, and nanotechnology could change the way kidney cancer is treated in India in the future. AI can assist doctors figure out how well a patient will respond to treatment, while nanotechnology can help drugs get to malignant regions without hurting good cells. Gene editing methods like CRISPR could be used to change stem cells so that they can better target cancer cells. India is putting more money into biotechnology and healthcare infrastructure; therefore it's conceivable that more hospitals will start using advanced stem cell techniques in the next ten years. More and more, kidney cancer care in India involves people from other fields. Instead than using just one strategy, oncologists use a combination of several therapy strategies to get the best results.
Cancer stem cells are very hard to kill, thus additional study is needed to find the best strategies to target and kill them. There are additional problems with cost, getting the necessary government clearances, and getting the word out to the public.
Conclusion
Regulatory organizations may authorize these medicines for wider usage as more clinical data becomes available. This would make them available to more kidney cancer patients across the country.
